0001104659-25-107873
SEC filingRevenue growth of 20% driven by DDS segment, with stable gross margin and improved adjusted EBITDA.
For the three months ended September 30, 2025, total revenue increased 20% to $62.6 million from $52.2 million in the prior-year period. The growth was primarily driven by a 23% increase in the Digital Data Solutions (DDS) segment, which benefited from higher volumes from existing customers. Gross profit rose to $25.5 million from $21.3 million, with gross margin remaining flat at 41%. Direct operating costs increased 20% to $37.0 million, largely due to higher headcount to support increased volumes. Selling and administrative expenses rose 38% to $13.7 million, driven by higher payroll and related costs. Net income decreased to $8.3 million from $17.4 million, primarily due to a significant swing in income tax provision—from a $5.9 million benefit in the prior year to a $3.8 million expense in the current period—along with higher operating costs. Basic earnings per share fell to $0.26 from $0.60. Adjusted EBITDA improved to $16.2 million from $13.9 million, reflecting better operational performance.
The DDS segment remained the primary growth engine, with revenue increasing 23% to $54.8 million. Gross margin for DDS improved to 40% from 39%, while adjusted gross margin rose to 43% from 41%. The segment's net income decreased to $8.4 million from $16.5 million due to higher income tax and operating costs. The Synodex segment saw revenue decline 11% to $1.7 million, with gross margin falling to 7% from 25%, driven by the termination of a customer contract. The segment was breakeven compared to net income of $0.4 million in the prior year. The Agility segment grew revenue 9% to $6.1 million, driven by higher subscriptions to its AI-enabled platform. However, gross margin decreased to 53% from 58%, and the segment reported a net loss of $0.1 million versus net income of $0.5 million in the prior year, due to higher direct and selling costs.
Management did not provide specific forward guidance in the MD&A. The company highlighted its focus on AI data preparation, model deployment, and AI-enabled industry platforms. It noted that capital expenditures for the next 12 months are anticipated to be approximately $11.0 million. The company believes existing cash and cash equivalents of $73.9 million are sufficient to meet liquidity needs for at least the next 12 months. Key risks include customer concentration (one DDS customer represented 56% of total revenue), potential contract terminations, and the at-will nature of project-based work.
Cash and cash equivalents more than doubled to $73.9M from $46.9M at December 31, 2024, driven by strong operating cash flows of $33.9M. The company maintains an undrawn $30M revolving credit facility, providing ample liquidity. Deferred revenue stood at $7.0M, down from $8.0M at year-end 2024.
Purchase commitments are minimal, consisting of a $0.1M remaining obligation under a Microsoft license agreement (annual payments of $0.4M through February 2026). The company also has operating lease commitments of $5.6M (undiscounted) with a weighted-average lease term of 41 months. A contingent liability exists from a Philippine legal judgment ($5.6M plus interest), but the company has a preliminary injunction preventing enforcement in the U.S.
No share repurchases or dividends were executed. Capital expenditures totaled $8.3M for the nine months, primarily for capitalized software development. Long-term debt increased by $0.4M to $8.8M, mainly due to higher pension obligations. No borrowings were made under the revolving credit facility.
Three segments: Digital Data Solutions (DDS) generated $156.2M (87% of total revenues), Synodex $5.7M (3%), and Agility $17.4M (10%). DDS operating income was $29.0M (18.6% margin), while Synodex posted $0.5M (9.2%) and Agility an operating loss of $0.6M. Geographically, U.S. customers accounted for $150.2M (84% of revenues), with Canada, UK, Netherlands, and other European countries comprising the remainder. One DDS customer represented 58% of total revenues for the nine months, indicating significant concentration.
Operating cash flow (CFO) of $33.9M significantly exceeded consolidated net income of $23.3M, reflecting strong cash conversion. Key non-cash add-backs included stock-based compensation ($8.3M), depreciation and amortization ($4.9M), and deferred income taxes ($3.2M). Working capital changes were a net use of cash, primarily driven by a $11.2M increase in accounts receivable, partially offset by a $6.9M increase in accounts payable. The large AR build may signal rapid revenue growth but warrants monitoring for collection trends.
Capital expenditures of $8.3M represented 24.5% of CFO, a moderate capex intensity. Free cash flow (not explicitly stated) would be approximately $25.6M (CFO minus capex), providing ample coverage for the minimal financing outflows. No share repurchases or dividends were paid. Financing activities were modest, with $1.5M in stock option proceeds and $0.4M in debt repayments. Cash and equivalents surged to $73.9M from $46.9M at the start of the period, bolstered by strong operational cash generation.